Heron Patrick J 4

What Happened
Patrick J. Heron, a non-employee director and 10% owner of MBX Biosciences, was granted a derivative award of 12,500 shares on 2026-06-04. The shares were acquired at $0.00 (total value $0 on grant) and are a compensatory award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-04; filing date: 2026-06-05 (appears timely).
• Grant type/code: A (award/grant of a derivative security).
• Shares granted: 12,500; acquisition price: $0.00; reported total value at grant: $0.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The award vests in full on the earlier of the one-year anniversary of the grant or the date of MBX’s next annual meeting of stockholders, subject to the director’s continued service.

Context
This is a typical director compensation award (likely restricted stock or RSUs) and does not represent an open-market purchase or sale. Such grants are routine for non-employee directors and reflect compensation, not necessarily a direct market sentiment signal from the insider.